Four multi-center, open-label, non-controlled trials have been conducted to evaluate the safety and efficacy of Novoeight in the on-demand treatment and control of breakthrough bleeds, routine prophylaxis and perioperative management in patients with hemophilia A. Three of these trials were performed in PTPs (two trials and one extension trial) and the fourth in PUPs. The analysis included 297 exposed subjects: 175 previously treated adolescents or adult subjects from the age of 12 years (≥150 exposure days), 63 previously treated pediatric subjects below the age of 12 years (≥50 exposure days) and 59 PUPs below 6 years of age. Immunocompetent patients with severe hemophilia A (factor VIII activity ≤1%) and no history of FVIII inhibitors were eligible for the trials. Subjects during routine prophylaxis and treatment of bleeds received Novoeight at the dose levels described in Tables 1 and 3. Breakthrough bleeds were treated at the investigator’s discretion aiming for a FVIII activity level above 0.5 IU/mL. Treatment during surgery was at the investigator’s discretion aiming for a FVIII trough activity level above 0.5 IU/mL.
On-demand Treatment and Control of Bleeding Episodes
A total of 3153 bleeds in 260 subjects were treated with Novoeight. The majority of the bleeds (90%) were of mild/moderate severity, 54% of the bleeds were spontaneous and 67% of the bleeds were localized in joints.
An overall assessment of efficacy was performed by the subject (for home treatment) or study site investigator (for treatment under medical supervision) using a four-point scale of excellent, good, moderate, or none. If the hemostatic response was rated as “excellent” or “good”, the treatment of the bleed was considered a success. If the hemostatic response was rated as “moderate or none” the treatment was considered a failure. Of these 3,153 bleeds, 2,809 (89%) were rated excellent or good in their response to treatment with Novoeight, 274 (9%) were rated as moderate, 25 (0.8%) were rated as having no response and for 45 (1%) the response to treatment was unknown. A total of 2,794 (89%) of the bleeds were resolved with one or two injections of Novoeight.
Of the 238 PTPs, 206 patients experienced 2,793 bleeds of which 2,492 (89%) were rated excellent or good in their response to treatment with Novoeight, 244 (9%) were moderate, 23 (0.8%) were rated as having no response, and for 34 (1%) the response to treatment was unknown. Of the 2,793 reported bleeds observed in 206 of the patients, 2,504 (90%) of the bleeds were resolved with 1–2 injections of Novoeight. The majority of the bleeds were of mild/moderate severity.
Of the 59 PUPs, 54 patients experienced 360 bleeds of which 317 (88%) were rated excellent or good in their response to treatment with Novoeight, 30 (8%) were moderate, 2 (0.6%) were rated as having no response, and for 11 (3%) the response to treatment was unknown. Of the 360 reported bleeds observed in 54 of the patients, 290 (81%) of the bleeds were resolved with 1–2 injections of Novoeight. The majority of the bleeds were of mild/moderate severity and the most frequent bleeds were subcutaneous.
Routine Prophylaxis
In the two trials, one trial including 150 adult/adolescent subjects (6 months duration) and the other trial including 63 pediatric subjects (4 months duration) received Novoeight for routine prophylaxis (Table 8). These previously treated patients received prophylaxis treatment every other day or three times weekly at the dose levels described in Table 3.
Table 8: Annualized Bleeding Rate (ABRa) for previously treated patients from the two trials
| Small children 0 - <6 years | Older children 6 - <12 years | Adolescents 12 - <18 years | Adults ≥18 years | Total |
Nb | 31 | 32 | 24 | 126 | 213 |
Median (IQR) | 2.97 (6.30) | 3.65 (8.93) | 3.98 (6.21) | 3.70 (9.02) | 3.67 (8.70) |
Mean (95%CI) | 4.77 (3.07; 7.41) | 5.93 (3.81; 9.22) | 5.48 (3.29; 9.14) | 6.69 (5.36; 8.36) | 6.24 (5.25; 7.41) |
a: The ABRs were estimated using a Poisson model allowing for overdispersion.
b: Patients dosed every other day or three times weekly
Abbreviations: N: number of patients; IQR: interquartile range defined as the difference between the 75th percentile and the 25th percentile; CI: confidence interval.
One hundred and eighty-eight (188) subjects from the two trials above continued into the extension trial (up to 6 years duration) (Table 9). Additionally, 18 subjects (7 subjects from an on-demand sub-trial and 11 subjects from a pharmacokinetic trial) were included in the extension trial. These previously treated patients received prophylaxis treatment every other day or three times weekly at the dose levels described in Table 3.
Table 9: Annualized Bleeding Rate (ABRa) for previously treated patients from the extension trial
| Small children 0 - <6 years | Older children 6 - <12 years | Adolescents 12 - <18 years | Adults ≥18 years | Total |
Nb | 27 | 28 | 23 | 128 | 206 |
Median (IQR) | 1.08 (2.83) | 1.57 (3.82) | 1.57 (2.34) | 1.38 (2.96) | 1.39 (2.94) |
Mean (95%CI) | 1.87 (1.14; 3.09) | 2.90 (2.01; 4.17) | 1.93 (1.33; 2.82) | 2.61 (2.08; 3.28) | 2.45 (2.07; 2.90) |
a: The ABRs were estimated using a Poisson model allowing for overdispersion.
b: Patients dosed every other day or three times weekly
Abbreviations: N: number of patients; IQR: interquartile range defined as the difference between the 75th percentile and the 25th percentile; CI: confidence interval.
In the trial with previously untreated patients, 56 subjects below 6 years of age received Novoeight for routine prophylaxis. The median annualized bleeding rate in the previously untreated patients was 2.9 (IQR 5.4) and the mean (95%CI) was 4.4 (3.3; 5.8).
Perioperative Management
A total of 30 surgeries were performed in 25 previously treated subjects between 8 and 58 years of age, of which 26 were major surgeries (20 orthopaedic, 5 non-orthopaedic and a circumcision), and 4 were minor (2 dental, 1 circumcision and 1 insertion of port-a-cath).
The investigator’s ratings of intra- and post-operative quality of hemostasis for these subjects were “excellent” or “good” for all cases.